- Clinical Interests
- Nasal polyposis
- Drug hypersensitivity
- Food sensitivity
- Eosinophilic disorders
- Medical Education
- MD, Northwestern University Medical School
- Residency, Duke University Medical Center
- Fellowship, Washington University School of Medicine
- Board Certifications
- Allergy & Immunology
- Diagnostic Laboratory Immunology
- Internal Medicine
- Boston: Massachusetts General Hospital
- Patient Gateway
- Yes, learn more
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
Dr. Hamilos joined the Division of Rheumatology, Allergy and Immunology at MGH as an Associate Physician in October 2003. He has expertise in asthma, allergic rhinitis, sinusitis, nasal polyposis, vasculitis, eosinophilic disorders and immune deficiency. Clinically, he is best known for his expertise in asthma and chronic sinusitis. In 2000, he developed algorithms for the diagnosis and management of chronic sinusitis that were published in the Journal of Allergy and Clinical Immunology. He has conducted workshops on fiberoptic rhinoscopy and lectured on chronic sinusitis pathogenesis and medical management at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology and/or the American College of Allergy, Asthma & Immunology each year from 1997 - 2010. He co-authored a monograph entitled: Chronic rhinosinusitis: Pathogenesis and Medical Management published by Informa Healthcare in 2007. He has been a contributing author to the internet-based medical publication UpToDate since 2007 on the subjects of: Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis and Management of chronic rhinosinusitis.
- Research Summary
My laboratory is investigating the pathogenesis of chronic rhinosinusitis (CRS). We are examining whether the nasal/sinus epithelium of CRS patients is lacking in the ability to produce innate immune factors involved in defense against infection. We are examining nasal/sinus tissue samples as well as cultured epithelial cells. We are currently examining innate immune and inflammatory gene expression in nasal/sinus tissues using broad-based mRNA expression profiling. These studies are supported by a grant from the Flight Attendants Medical Research Institute (FAMRI) as well as a Harvard Catalyst Grant. It is our hope that these studies will lead to a greater understanding of CRS pathogenesis and help identify novel therapies.
I am also a co-investigator with Dr. Andrew Luster in an NIH funded project aimed at understanding the role of chemokines and Th2 cellular trafficking in asthma. I am responsible for recruitment and preparation of subjects for bronchoscopy and bronchoalveolar lavage. Each subject's allergic sensitivity to house dust mite and cat allergen is first determined by skin test titration. Subsequently, each subject undergoes bronchoscopy with seqmental allergen challenge followed 24 hours later by bronchoscopy with bronchoalveolar lavage. We are also comparing the inflammatory response to allergen in allergic nonasthmatics versus allergic asthmatics to determine whether cellular inflammation can account for the asthmatic response. It is our hope that these studies will help elucidate the mechanisms that control the asthmatic response and the link between allergic airway inflammation and airway hyperesponsiveness.
1. Hamilos DL, Baroody FM, editors. Chronic Rhinosinusitis: Pathogenesis and Medical Management. New York: Informa Healthcare; 2007.
2. Banerji A, Piccirillo JF, Thawley SE, Levitt RG, Schechtman KB, Kramper MA, Hamilos DL. Chronic rhinosinusitis patients with polyps or polypoid mucosa have a greater burden of illness. Am J Rhinology 2007;21:19-26.
3. Hamilos DL, D'Urzo A, Levy RJ, Marcus M, Tripp K, Parsey M, Baumgartner RA, McVicar WK. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol. 2007;99(6):540-8.
4. Yamin M, Holbrook EH, Gray ST, Harold R, Busaba N, Sridhar A, Powell KJ, Hamilos DL Cigarette smoke combined with Toll-like receptor 3 (TLR3) signaling triggers exaggerated epithelial RANTES/CCL5 expression in chronic rhinosinusitis (CRS). J Allergy Clin Immunol 2008; 122:1145-1153. PMID: 18986692
5. Hamilos DL. Allergic fungal rhinitis and rhinosinusitis. Proc Am Thorac Soc. 2010;7(3):245-52.
55 Fruit Street
Boston MA, 02114-2696